WO1997026320A3 - Product for inhibition of attachment of h. influenzae to human cells - Google Patents

Product for inhibition of attachment of h. influenzae to human cells Download PDF

Info

Publication number
WO1997026320A3
WO1997026320A3 PCT/US1996/017971 US9617971W WO9726320A3 WO 1997026320 A3 WO1997026320 A3 WO 1997026320A3 US 9617971 W US9617971 W US 9617971W WO 9726320 A3 WO9726320 A3 WO 9726320A3
Authority
WO
WIPO (PCT)
Prior art keywords
product
influenzae
attachment
casein
inhibition
Prior art date
Application number
PCT/US1996/017971
Other languages
French (fr)
Other versions
WO1997026320A2 (en
Inventor
Pradip Mukerji
Jennifer Marie Thurmond
Lennart Hansson
Jennifer Harris Baxter
Robert George Hards
Amanda Eun-Yeong Leonard
Steven Neal Anderson
Linda Ann Harvey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP09525977A priority Critical patent/JP2000503319A/en
Priority to DE69629487T priority patent/DE69629487D1/en
Priority to AT96942738T priority patent/ATE246934T1/en
Priority to EP96942738A priority patent/EP0859629B1/en
Priority to AU11581/97A priority patent/AU1158197A/en
Publication of WO1997026320A2 publication Critical patent/WO1997026320A2/en
Publication of WO1997026320A3 publication Critical patent/WO1997026320A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A product is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human β-casein that have at least 3 phosphate groups. The product containing phosphorylated recombinant human β-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human β-casein may also be administered as a throat spray or used in nose drops or a spray.
PCT/US1996/017971 1995-11-06 1996-11-06 Product for inhibition of attachment of h. influenzae to human cells WO1997026320A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP09525977A JP2000503319A (en) 1995-11-06 1996-11-06 Products for preventing Haemophilus influenzae from attaching to human cells
DE69629487T DE69629487D1 (en) 1995-11-06 1996-11-06 PHOSPHORYLATED RECOMBINANT HUMAN BETA-CASEIN FOR INHIBITING THE INFLUENCE OF H. INFLUENZAE ON HUMAN CELLS
AT96942738T ATE246934T1 (en) 1995-11-06 1996-11-06 PHOSPHORYLATED RECOMBINANT HUMAN BETA CASEIN FOR INHIBITING THE ADDHESION OF H. INFLUENZAE TO HUMAN CELLS
EP96942738A EP0859629B1 (en) 1995-11-06 1996-11-06 Phosphorylated recombinant human beta casein for inhibition of attachment of h. influenzae to human cells
AU11581/97A AU1158197A (en) 1995-11-06 1996-11-06 Product for inhibition of attachment of h. influenzae to human cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55394195A 1995-11-06 1995-11-06
US08/553,941 1995-11-06

Publications (2)

Publication Number Publication Date
WO1997026320A2 WO1997026320A2 (en) 1997-07-24
WO1997026320A3 true WO1997026320A3 (en) 1997-09-12

Family

ID=24211413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017971 WO1997026320A2 (en) 1995-11-06 1996-11-06 Product for inhibition of attachment of h. influenzae to human cells

Country Status (8)

Country Link
EP (1) EP0859629B1 (en)
JP (1) JP2000503319A (en)
AT (1) ATE246934T1 (en)
AU (1) AU1158197A (en)
CA (1) CA2234680A1 (en)
DE (1) DE69629487D1 (en)
MX (1) MX9803568A (en)
WO (1) WO1997026320A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968901A (en) * 1989-10-30 1999-10-19 Andersson; Bengt Antibacterial composition
JP2000500141A (en) * 1995-11-06 2000-01-11 アボツト・ラボラトリーズ Method for inhibiting adhesion of Haemophilus influenzae to human cells using phosphorylated recombinant human beta-casein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (en) * 1989-10-30 1991-05-16 Bengt Andersson A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
WO1996027018A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
WO1997017085A2 (en) * 1995-11-06 1997-05-15 Abbott Laboratories A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
WO1997017449A1 (en) * 1995-11-06 1997-05-15 Abbott Laboratories A method for expressing phosphorylated recombinant human beta-casein in a bacterial system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795611A (en) * 1989-12-20 1998-08-18 Slattery; Charles W. Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006308A1 (en) * 1989-10-30 1991-05-16 Bengt Andersson A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
WO1996027018A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
WO1997017085A2 (en) * 1995-11-06 1997-05-15 Abbott Laboratories A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
WO1997017449A1 (en) * 1995-11-06 1997-05-15 Abbott Laboratories A method for expressing phosphorylated recombinant human beta-casein in a bacterial system

Also Published As

Publication number Publication date
WO1997026320A2 (en) 1997-07-24
AU1158197A (en) 1997-08-11
JP2000503319A (en) 2000-03-21
EP0859629A2 (en) 1998-08-26
CA2234680A1 (en) 1997-07-24
MX9803568A (en) 1998-09-30
ATE246934T1 (en) 2003-08-15
EP0859629B1 (en) 2003-08-13
DE69629487D1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
NZ333695A (en) Method for treating gastrointestinal damage with hyperimmunised milk and hyperimmunised egg
EP0379806A3 (en) Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
CA2151604A1 (en) Application of riluzole in the treatment of neurological lesions associated with traumas
EP0486425A3 (en) High acid system nutritional formulations
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
EP1013284A3 (en) Purified forms of dnase
ATE272947T1 (en) BIFIDOBACTERIUM GROWTH PROMOTER
PL312225A1 (en) Novel chemical compounds exhibiting pde iv inhibiting activity
CA2045077A1 (en) Anti-epileptics
AU688803B2 (en) Method for treatment for pulmonary disease
AU7405091A (en) Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
WO1997017085A3 (en) A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
Larson et al. Frequency of eating as a factor in experimental dental caries
WO1997026320A3 (en) Product for inhibition of attachment of h. influenzae to human cells
GB8402573D0 (en) Oral formulation
MY132751A (en) Pogostemon cablin extract for inhibiting h. influenzae adhesion and treating otitis media or sore throat
JPS57106618A (en) Anticancer agent consisting of polyprenyl compound
MX9605829A (en) Inhibition of attachment of h. influenzae to human cells.
Shaw The role of sugar in the aetiology of dental caries: 6. Evidence from experimental animal research
EP0613375A4 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof.
MX9605830A (en) Inhibition of infection of mammalian cells by respiratory syncytial virus.
Neu Use of cephalosporins in the treatment of bacterial menigitis.
GB2182558A (en) Oral fructo-oligosaccharide pharmaceutical compositions
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
NZ285593A (en) An enteral nutritional product containing casein that is sufficient to inhibit infection of mammalian cells by human rotavirus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996942738

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2234680

Country of ref document: CA

Ref country code: CA

Ref document number: 2234680

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 525977

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/003568

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1996942738

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996942738

Country of ref document: EP